Torsten Madsen

Dr. Torsten Madsen is a Physician Scientist with more than 20 years of international experience in Neuroscience Drug Development and Clinical Research. He earned his MD and PhD degrees from the University of Copenhagen, followed by clinical training in Internal Medicine and Psychiatry, and postdoctoral research at Yale University School of Medicine and the Instituto Cajal in Madrid. Dr. Madsen has led programs across all phases of drug development, from discovery through clinical proof-of-concept and registration, covering a broad range of CNS disorders including depression, schizophrenia, pain, epilepsy, and neurodegeneration.

He has held senior leadership positions in both biotech and pharmaceutical companies. As Chief Medical Officer at Syndesi Therapeutics, he guided the development of SV2A modulators for cognitive disorders until the company’s acquisition by AbbVie. Prior to that, he served as Chief Medical Officer at Aptinyx and as Vice President at Naurex, which was acquired by Allergan. Earlier in his career, he held multiple leadership roles at H. Lundbeck A/S, where he contributed to the global approval of the antidepressant vortioxetine. Before joining IAMA Therapeutics, Dr. Madsen was CEO of Hoba Therapeutics, a biotech company developing biologics for pain and hearing loss.